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Background
The diagnosis, prognosis, and treatment of acute myeloid
leukemia (AML) have been transformed to be based on
genetic, genomic, and molecular characteristics of the dis-
ease. Wilms’ tumour (WT1) is an important regulatory
molecule involved in cell growth and development [1-3].
WT1 is highly expressed in the bone marrow or peripheral
blood of a variety of leukemia.
Materials and methods
This study was designed to investigate the involvement of
WT1 gene mutation in the development of Acute Myeloid
Leukemia in Sudan. The study involved 51 patients and 75
healthy controls. Genomic DNA was isolated from periph-
eral blood leukocytes using salting out method. PCR
amplification of the target sequence (214 bp) within exon7
of WT1 gene was carried out. The known A®G transition
mutation that destroys an AflIII restriction enzyme recog-
nition site was detected by RFLP analysis.
Results
The study revealed that 43.14% of cases (22/51 patients)
were heterozygous A/G and only 3.92% (2/51) were homo-
zygous G/G for the mutant allele on the other hand
26.67% (20/75 controls) were heterozygous A/G and the
homozygous G/G genotype was not observed in any of the
controls. The study showed a significant difference in the
frequency of the mutant WT1 allele between patients
25.49% and controls 13.33%.
Conclusions
In the Sudanese population, the Wilms’ tumour (WT1)
gene A®G mutation appears to be associated with
increased risk of developing Acute Myeloid Leukemia.
The disease was found to be associated with the hetero-
zygous genotype.
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